搜尋

file (3)

What We Do

學術發表

首頁學術發表

2023.Apr.04

ADC

OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab

Poster

2023.Mar.24

Vaccine

Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies

2023.Jan.26

ADC

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

2022.Jun.22

Vaccine

The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer

2022.Jun.06

Vaccine

A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer

Poster

2022.Jun.05

ADC

First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors

Poster

2022.Jun.02

Prodrug

Safety, pharmacokinetics, and clinical activity of OBI-3424, an AKR1C3-activated prodrug, in patients with advanced or metastatic solid tumors: A phase 1 dose-escalation study.

Poster

2022.Apr.09

Vaccine

High Globo-H expression associated with poor survival of gastric cancer patients and enriched PD-L1 expression

Poster

2022.Apr.09

Prodrug

OBI-3424, an AKR1C3-activated prodrug, exhibits in vivo synergistic anti-tumor effect in combination with pembrolizumab by induction of immunogenic cell death

Poster

2021.Nov.04

Vaccine

The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targets